Autolus Therapeutics plc - American Depositary Shares (AUTL)
AUTL moved a median of -0.00% 30 minutes after news, and -0.65% by the close. How AUTL actually reacts to news — the realized, point-in-time move the market made, measured across 377 labeled events over the last three years with zero look-ahead.
AUTL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 374 |
| 30-min | -0.00% | 45% | 376 |
| 60-min | -0.29% | 46% | 376 |
| to close | -0.65% | 42% | 372 |
| Middle 50% of AUTL reactions | -1.47% to +1.15% |
|---|---|
| Median reaction (30-min) | -0.00% |
| Measured reactions | 377 |
Half of all Autolus Therapeutics plc - American Depositary Shares news events land between -1.47% and +1.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AUTL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | -2.15% | 31% | -2.53% |
| Rating reiterations | 58 | +0.07% | 52% | -1.12% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how AUTL ranks against every other measured name →
That’s how AUTL usually reacts — get an email when it moves on news →Email me when AUTL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AUTL's baseline. Nothing else.
Recent AUTL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Engitix appoints Ryan Richardson to Board of Directors as company advances towards clinical development | Press release | GlobeNewswire | +0.62% | +4.97% | |
| Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 | Press release | GlobeNewswire | -0.06% | +2.81% | |
| Form EFFECT Autolus Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -0.73% | -4.41% | |
| Form DEL AM Autolus Therapeutics | SEC filing · Form DEL | SEC EDGAR | -0.52% | -3.11% | |
| Form S-3 Autolus Therapeutics | SEC filing · Form S-3 | SEC EDGAR | +0.27% | +4.30% | |
| Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis | Press release | GlobeNewswire | -0.72% | -2.87% | |
| CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight | Press release | PR Newswire | +0.00% | -2.98% | |
| Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | +3.92% | +14.22% | |
| Form 10-Q Autolus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.28% | -9.40% | |
| Form 8-K Autolus Therapeutics For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +3.92% | +14.22% | |
| Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors | Press release | GlobeNewswire | -5.23% | +5.81% | |
| Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 | Press release | GlobeNewswire | +4.97% | +7.74% | |
| Form 8-K Autolus Therapeutics For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -5.23% | +5.81% | |
| Form 8-K Autolus Therapeutics For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -5.23% | +5.81% | |
| Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.21% | -1.25% | |
| Form 8-K Autolus Therapeutics For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | -2.44% | |
| Autolus Therapeutics to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | +0.62% | -1.24% | |
| Autolus Therapeutics Receives Prix Galien UK Award | Press release | GlobeNewswire | -0.95% | -0.64% | |
| The Galien Foundation Honours Leaders in Life Sciences Innovation with the 2026 Prix Galien UK Awards | Press release | PR Newswire | -0.95% | -0.64% | |
| Form 8-K Autolus Therapeutics For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.35% | |
| T-cell Malignancies Market to Accelerate Substantially at a CAGR of 5.2% During the Forecast Period (2026-2036) | DelveInsight | Press release | PR Newswire | +0.23% | -5.54% | |
| Autolus Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.48% | -0.59% | |
| Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 | Press release | GlobeNewswire | +2.69% | +1.80% | |
| Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development | Press release | GlobeNewswire | +6.17% | +11.11% | |
| Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | -4.49% | +1.92% | |
| Form 10-Q Autolus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.63% | +3.17% | |
| Form 8-K Autolus Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -4.49% | +1.92% | |
| The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product," "Best Public Sector Innovation" and "Best Health Equity Innova | Press release | PR Newswire | -0.64% | +1.91% | |
| Form EFFECT Autolus Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -2.07% | +0.59% | |
| Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 | Press release | GlobeNewswire | +0.63% | +2.50% | |
| Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction | Press release | GlobeNewswire | +1.43% | +0.71% | |
| Form 8-K Autolus Therapeutics For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +1.43% | +0.71% | |
| Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer | Press release | Business Wire | +0.70% | +4.22% | |
| Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition | Press release | GlobeNewswire | +1.63% | +4.58% | |
| Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.63% | +4.58% | |
| Form 8-K Autolus Therapeutics For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +1.86% | -0.62% | |
| Form DEL AM Autolus Therapeutics | SEC filing · Form DEL | SEC EDGAR | -0.34% | +0.00% | |
| Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development | Press release | GlobeNewswire | +2.04% | +0.68% | |
| Form S-3 Autolus Therapeutics | SEC filing · Form S-3 | SEC EDGAR | +1.71% | +0.69% | |
| Form 8-K Autolus Therapeutics For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | -1.34% | |
| Autolus Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.25% | +1.36% | |
| Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Press release | GlobeNewswire | -1.24% | +0.00% | |
| Form 10-K Autolus Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.85% | +3.25% | |
| Form 8-K Autolus Therapeutics For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +0.00% | |
| Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 | Press release | GlobeNewswire | -0.66% | -0.66% | |
| CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight | Press release | PR Newswire | -0.01% | -1.89% | |
| Autolus Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.29% | +4.00% | |
| CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™ | Press release | PR Newswire | +0.72% | +7.09% | |
| Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.92% | +0.73% | |
| Form 8-K Autolus Therapeutics For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | +2.16% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AUTL section they belong to.
Where else AUTL is measured.
AUTL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | 377 | 0.00% | 49% |
| Amneal Pharmaceuticals, Inc. - Class A (AMRX) | 377 | -0.08% | 46% |
| Solid Biosciences Inc. (SLDB) | 375 | -0.17% | 46% |
| Halozyme Therapeutics, Inc. (HALO) | 374 | -0.11% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Autolus Therapeutics plc - American Depositary Shares's median reaction calculated?
Every labeled AUTL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 377 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of AUTL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AUTL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.